title: Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
abstract: The t(11;14)(q13;q32) translocation is seen in 15%-20% patients with multiple myeloma (MM). It generally is not associated with worse outcomes. We studied the impact of t(11;14)(q13;q32) on outcome in patients with MM who received high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HCT). Eligible patients underwent high-dose chemotherapy followed by auto-HCT at the M.D. Anderson Cancer Center between February 2000 and August 2010, and had conventional cytogenetic (CC) or fluorescence in situ hybridization (FISH) results available before auto-HCT (n = 993). The cohort was divided into 3 groups of patients: (1) normal (diploid by CC and negative by FISH; n = 869); (2) t(11;14)(q13;q32) by CC or FISH (n = 27); and (3) high-risk (HR) abnormalities by CC or FISH (n = 97). Of the 27 patients with t(11;14)(q13;q32), 18 had isolated t(11;14)(q13;q32) and 9 had concurrent HR abnormalities. The primary objective was to compare outcomes in patients with t(11;14)(q13;q32) and patients with diploid or HR markers detected by CC or FISH studies. The median duration of follow-up in surviving patients was 37 months. The 3-year progression-free survival (PFS) was 47% for the normal group, 27% for the t(11;14)(q13;q32) group, and 13% for the HR group (P < .00001). The 3-year OS was 83% for the normal group, 63% for the t(11;14)(q13;q32) group, and 34% for the HR group (P < .00001). On multivariate analysis, t(11;14)(q13;q32) and HR abnormalities by CC or FISH and relapsed disease at auto-HCT were associated with shorter PFS, whereas t(11;14)(q13;q32) and HR abnormalities by CC or FISH, β2 microglobulin of >3.5, and relapsed disease at the time of auto-HCT were associated with shorter OS. In conclusion, patients with t(11;14)(q13;q32) had worse outcomes than patients with normal CC or FISH studies, but better outcomes than patients with HR markers detected by CC or FISH studies.
authors.affiliation: Department of Medicine, Beth Israel Medical Center, New York, NY 10003, USA. koji_1225shasha@yahoo.co.jp
authors.forename: Koji
authors.initials: K
authors.lastname: Sasaki
authors.forename: Gary
authors.initials: G
authors.lastname: Lu
authors.forename: Rima M
authors.initials: RM
authors.lastname: Saliba
authors.forename: Qaiser
authors.initials: Q
authors.lastname: Bashir
authors.forename: Chitra
authors.initials: C
authors.lastname: Hosing
authors.forename: Uday
authors.initials: U
authors.lastname: Popat
authors.forename: Nina
authors.initials: N
authors.lastname: Shah
authors.forename: Simrit
authors.initials: S
authors.lastname: Parmar
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Dinh
authors.forename: Sairah
authors.initials: S
authors.lastname: Ahmed
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: Partow
authors.initials: P
authors.lastname: Kebriaei
authors.forename: Jatin J
authors.initials: JJ
authors.lastname: Shah
authors.forename: Robert Z
authors.initials: RZ
authors.lastname: Orlowski
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
authors.forename: Muzaffar H
authors.initials: MH
authors.lastname: Qazilbash
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002880:Chromosomes, Human, Pair 11; D002883:Chromosomes, Human, Pair 14; D003582:Cytogenetics; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000276:immunology / Q000601:surgery*; D011379:Prognosis; D012189:Retrospective Studies; D014178:Translocation, Genetic; D014182:Transplantation, Autologous; D016896:Treatment Outcome
keywords: Autologous transplantation; Cytogenetics; Myeloma; t(11;14)